Boothbay Fund Management’s CorMedix CRMD Stock Holding History

Boothbay Fund Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,360	Closed	-$42K	–	2294
2022 Q2	$42K	Buy	+10,360	New	+$38.5K	﹤0.01%	2089

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boothbay Fund Management's CRMD Position: Q3 2022 in Review

Boothbay Fund Management sold out of CorMedix (CRMD) in Q3 2022, closing a stake of 10,360 shares — an estimated $42K sold.

Boothbay Fund Management first reported a position in CRMD in Q2 2022 and held it in 1 quarter. The position peaked at $42K in Q2 2022. 73 funds tracked by Wall St. Rank hold CRMD as of Q3 2022.

Boothbay Fund Management reported no remaining CorMedix position as of Q3 2022 after selling out during the quarter.
Boothbay Fund Management sold 10,360 CorMedix shares in Q3 2022, an estimated $42K.
Boothbay Fund Management first reported a position in CorMedix in Q2 2022 and held it in 1 quarter.
Boothbay Fund Management's CorMedix position peaked at $42K in Q2 2022.
73 funds tracked by Wall St. Rank held CorMedix as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.